… Chronic effect of phosphodiesterase type 5 inhibitors on … with increased cardiovascular
risk (tadalafil). (B) Favorable … Chronic effect of phosphodiesterase type 5 inhibitors on arterial …

… Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor
Sildenafil. J … Type V phosphodiesterase expression in cerebral arteries with vasospasm after …

… preliminary findings have suggested that phosphodiesterase type 5 inhibition represents a
promising treatment strategy for a range of cardiovascular conditions, including hypertension …

… for the antihypertensive effect to begin to wane, which may be of clinical relevance given
that the early morning surge in BP may be an important trigger of cardiovascular events. The …

… , heart rate, or cardiac output. Coronary hemodynamics … Taken together, no significant
adverse cardiovascular effects … use imparts a beneficial cardiac inotropic effect together with anti-…

… combining milrinone with a PDE type V inhibitor (sildenafil, zaprinast) and also with prostacyclin
and inhaled NO. Overall, combination of milrinone with a type V inhibitor appears to be …

… In this review, we try to outline the effects of PDE 5 inhibition in addition to its efficacy in
erectile dysfunction. Potential implications, and whether some of these effects are therapeutically …

… In particular, how are the cardiac effects being generated, what conditions will they most
likely be applicable to, and why? Why does it apparently take much higher levels of sildenafil to …

… using the following search terms: (phosphodiesterase type 5 inhibitor OR sildenafil OR Viagra
OR … OR Vivanza) AND (cardiovascular OR myocardial OR infarct OR cardiac OR heart OR …

… reviewed the overall cardiovascular profile of sildenafil, the first PDE5 inhibitor to be approved
by the Food and Drug Administration (FDA). The cardiovascular effects of sildenafil, given …